GLP-1 research expands: oral Wegovy and ‘beyond GLP-1’ targets

The FDA’s public comment window on whether to keep three popular GLP-1 medicines off the 503B bulk drug substances list closes June 29, 2026. In an April 30, 2026 proposal, the FDA said it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances, given that FDA-approved versions…

The FDA’s Pharmacy Compounding Advisory Committee will review BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon for the 503A compounding bulks list.

A review in Frontiers in Bioinformatics surveys how big data, modeling and AI are advancing computational antimicrobial peptide (AMP) discovery — a methods-focused look at the research.

BPC-157 came off the 503A Category 2 safety-risk list in April 2026 but is not yet on an approved bulks list, leaving its compounding status unresolved ahead of the July PCAC review.

Researchers at Kyushu University report a coumarin-tag method in Analytical Chemistry that improves accurate de novo sequencing of short peptides by mass spectrometry.

Several procedural deadlines for the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting on peptides fall within the next few weeks. The committee is scheduled to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon, in their free-base and acetate forms — should be eligible for compounding under…